Elucidation of the molecular mechanisms by which CAV1 loss mediates lipid accumulation in liver steatosis may have an important clinical impact, and hence, gene-therapy approaches to overexpress CAV1 might be of utility to ameliorate or even reverse NAFLD in humans. The gene discussed is CAV1; the disease is fatty liver disease.